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Abstract
Chagas disease caused by Trypanosoma cruzi is an important cause of mortality and morbidity in Latin America but no
vaccines or safe chemotherapeutic agents are available. Combined therapy is envisioned as an ideal approach since it may
enhance efficacy by acting upon different cellular targets, may reduce toxicity and minimize the risk of drug resistance.
Therefore, we investigated the activity of benznidazole (Bz) in combination with the diamidine prodrug DB289 and in
combination with the arylimidamide DB766 upon T. cruzi infection in vivo. The oral treatment of T.cruzi-infected mice with
DB289 and Benznidazole (Bz) alone reduced the number of circulating parasites compared with untreated mice by about
70% and 90%, respectively. However, the combination of these two compounds decreased the parasitemia by 99% and
protected against animal mortality by 100%, but without providing a parasitological cure. When Bz (p.o) was combined with
DB766 (via ip route), at least a 99.5% decrease in parasitemia levels was observed. DB766+Bz also provided 100% protection
against mice mortality while Bz alone provided about 87% protection. This combined therapy also reduced the tissular
lesions induced by T. cruzi infection: Bz alone reduced GPT and CK plasma levels by about 12% and 78% compared to
untreated mice group, the combination of Bz with DB766 resulted in a reduction of GPT and CK plasma levels of 56% and
91%. Cure assessment through hemocultive and PCR approaches showed that Bz did not provide a parasitological cure,
however, DB766 alone or associated with Bz cured $13% of surviving animals.
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Introduction
Discovered by the Brazilian physician Carlos Chagas one
century ago, Chagas disease (CD) is a zoonosis caused by
kinetoplastid flagellated Trypanosoma cruzi [1]. It is well known
that CD is an endemic illness in poor areas of 15 developing
countries of Latin America, affecting about 12 to 14 million
people. Less well known is that CD is becoming a health problem
in non-endemic areas such as Europe and United States largely
due to the migration of infected people to these regions [2–4]. Due
to the lack of an efficient therapy, mainly for chronic chagasic
patients, and since it has been considered by many pharmaceutical
industries to have limited economical potential, CD has been
designated a neglected tropical disease [5].
The main route of transmission of T. cruzi infection to humans is
through the feces of blood-sucking triatomine insects but other
routes also exist including blood transfusion, transplacentally,
organ transplantation, laboratory accidents and oral ingestion of
contaminated food [6–12]. CD is the leading cause of infectious
myocarditis worldwide, which is one of its most serious and
frequent clinical manifestations observed during the chronic phase
of the disease that appears in about 20–40% of infected individuals
years or decades after the acute infection [13–15]. The available
treatment is based on two nitroheterocycles: nifurtimox (4-[(5-
nitrofurfurylidene)-amino]-3-methylthio morpholine-1,1-dioxide),
a nitrofuran produced only in El Salvador by WHO-Bayer, and
benznidazole (N-benzyl-2-nitro-1-imidazoleacetamide), a nitroimi-
dazole produced by LAFEPE-Brazil. Both are indicated for the
treatment of all acute and early chronic cases, exhibiting about
60–80% efficacy [16]. Nevertheless, neither compound is highly
effective against the late chronic phase (about 20% cures), both
require long-term therapy in addition to displaying side-effects that
can lead to interruption of the treatment. These deficiencies justify
the search for new chemotherapeutic options [5,17,18,19].
Many studies have demonstrated the excellent activity of
aromatic diamidines (AD), pentamidine and related compounds,
against many pathogens, such as bacteria, fungi and protozoa
[20]. Although the exact mechanism of action is still not precisely
known, it has been proposed that the binding of these cationic
molecules in the DNA minor groove, mainly at AT-rich regions,
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[16,21–22]. We have previously reported the in vitro and in vivo
activity of AD and analogues such as arylimidamides (AIA) upon
T.cruzi [23–26]. A recent study demonstrated that the AIA, DB766
shows superior efficacy than Bz upon different parasite strains,
including those naturally resistant to Bz [27].
Combination therapy represents a promising approach for the
enhancement of drug efficacy since it (i) allows the use of at least
two compounds that may act upon different cellular elements and
metabolic pathways (ii) may reduce drug concentrations and
number of doses thus contributing to the lowering of toxic effects,
and (iii) may minimize the risk of drug resistance [28]. For the
reasons stated above, the combination of different trypanocidal
compounds merits exploration [16,28–29]. Our present goal is to
evaluate in vivo the combined effect of Bz with the prodrug DB289
and with the arylimidamide DB766, to determine if a scheme of
therapy with these drugs could reduce toxicity and improve
efficacy in an animal model for Trypanosoma cruzi-infection.
Materials and Methods
Compounds
The aromatic diamidine DB289 (pafuramidine maleate; 2,5-
bis[4-(N-methoxyamidino)phenyl]furan monomaleate) and the
arylimidamide DB766 (Fig. 1) were synthesized according to
methodology previously reported by us [30–32]. A DB289 stock
solution was made in a solvent consisting of sterile distilled water
(99.4%), Tween 80 (0.1%), and ethanol, which was freshly
prepared immediately before use each day. The route of
administration used was oral gavage. DB289 and DB766 were
dissolved in DMSO and then freshly diluted with sterile distilled
water before use by intraperitoneal (ip.) or p.o. routes. The stock
solution of Benznidazole (N-benzyl-2-nitroimidazol acetamide,
Rochagan, Roche) was prepared in sterile distilled water with
3%Tween 80, and before use was diluted in sterile distilled water
for p.o. administration.
Parasites
Bloodstream trypomastigotes (BT) of the Y strain were used
throughout and were harvested by heart puncture from T. cruzi-
infected Swiss mice on the day of peak parasitemia, as described
[33].
Mice infection
Male Swiss mice (20–24 g) were obtained from the animal
facilities of the Oswaldo Cruz Foundation (CECAL, Rio de
Janeiro, Brazil). Mice were housed at a maximum of 8 per cage
and kept in a specific pathogen free (SPF) room at 20–24uC under
a 12/12 h light/dark cycle and provided with sterilized water and
chow ad libitum. The animals were allowed to acclimate for 7 days
before starting the experiments. Infection was performed by ip
injection of 10
4 BT. Age-matched non-infected mice were
maintained under identical conditions.
Treatment schemes
The animals were divided into the following groups (Table 1):
uninfected (non-infected and non-treated); untreated (infected but
non-treated); and treated (infected and treated with the different
compounds combined or not with Bz) [24–25]. Drug therapy was
performed by 20 daily consecutive doses (ip. and p.o., Table 1),
starting at the onset of the parasitemia (5 dpi). In all assays, only
mice with positive parasitemia were used in the infected groups.
Parasitemia, mortality rates and ponderal curve analysis
The level of parasitemia was checked by the Pizzi–Brener
method. Mice were individually checked by direct microscopic
counting of parasites in 5 mL of blood [34]. The mortality rates
were checked daily until 60 dpi and expressed as cumulative
mortality (% CM). Body weight was evaluated from 0 up to
60 dpi, and expressed as percentage of weight variation [24–25].
Histopathological analysis
At 14 dpi (peak of cardiac parasitism and inflammation in this
experimental model as described in de Souza et al., 2006 [24], the
heart tissues were removed, cut longitudinally, rinsed in ice-cold
phosphate buffered saline (PBS), and fixed in Millonig-Rosman
solution (10% formaldehyde in PBS). The tissues were dehydrated
and embedded in paraffin. Sections (3 mm) were then stained with
hematoxylin-eosin and analyzed by light microscopy. The number
of amastigote nests was determined in at least 60 fields (total
magnification, 406) for each slide. The mean number of
amastigotes’ nests per field was obtained from at least three mice
per group, with three sections from each mouse.
Biochemical analysis
At 14 day post infection (dpi), mice blood was collected and
immediately submitted to analysis for biochemical determination
of plasma tissular markers including glutamate pyruvate transam-
inase (GPT) and total creatine kinase (CK) using the Reflotron
System (Roche Diagnostics, F. Hoffmann-La Roche Ltd, Basel,
Switzerland) [35].
Cure assessment
Cure criteria were based on two parasitological methods:
polymerase chain reaction (PCR) and hemoculture assays which
detect kDNA minicircle specific sequences or the parasite itself,
respectively. Animals presenting negative results by both tests were
Figure 1. Chemical structures of DB289 (A) and DB766 (B).
doi:10.1371/journal.pone.0022155.g001
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700 mL of blood were collected from the heart of anesthetized
mice and then 500 mL and 200 mL were used for PCR and
hemoculture analysis, respectively. For PCR, the blood was diluted
in 1:3 volume of guanidine solution (6 M guanidine-HCl/0.2 M
EDTA), and heated for 90 s in boiling water in order to cleave the
parasite kDNA network [36] and the PCR performed using the
primers: (59AAATAATGTACGGG(T/G)GAGATGCATGA39)
and (59GGTTCGATTGGGGTTGGTGTAATATA39), which
amplify a 330 bp sequence from the kinetoplast DNA (aprox
120 000 copies per parasite), as previously described by Wincker
et al. (1994) [37]. The PCR was carried out using a GeneAmpH
PCR System 9700 (Applied Biosystems) as follows: one step at
94uC for 3 min (to activate the Taq DNA polymerase), 2 cycles at
98uC for 1 min and 64uC for 2 min, 38 cycles at 94uC for 1 min
and 64uC for 1 min, followed by a final extension at 72uC for
10 min. The amplification products were detected on a 1.5%
agarose gel electrophoresis following staining with ethidium
bromide (5 mg/mL). For hemoculture, 200 mL of blood was
added to 5 mL LIT medium and incubated at 28uC for 60 days,
being weekly examined by light microscopy to detect epimastigote
forms [38].
All procedures were carried out in accordance with the
guidelines established by the FIOCRUZ Committee of Ethics
for the Use of Animals (protocol approved - CEUA 0099/01).
Results
Since (i) in a previous study we found that a phenyl-substituted
analogue of furamidine gave a trypanocidal effect upon a T. cruzi
infection in vivo [23], and (ii) oral administration of only two doses
at onset (5 dpi) and at parasitemia peak (8 dpi) of 25 and 50 mg/
kg/day of the furamidine prodrug (DB289) resulted in about a
60% decrease of parasitemia (Fig. 2A), we evaluated the
combination of DB289 with Bz to determine if an enhancement
of efficacy against the parasite was observed. Our results show that
although treatment with 25 mg/kg/day of DB289 or 50 mg/kg/
day of Bz, both alone, lowered the parasitemia peak levels by
about 70% and 90%, the combined treatment reduced the
number of circulating parasites at 8 dpi by more than 99%
(Fig. 2B; Table 2). Mice survival rates of about 85% and 40% were
found for DB289 treated and untreated mice groups, respectively.
The combination of the prodrug DB289 with Bz resulted in 100%
animal survival (Fig. 2C). At three weeks post infection when the
highest body weight lose is observed in this T. cruzi experimental
model [27], both DB289 alone and Bz+DB289 showed consider-
able lose of mice body weight similar to or even as high as that for
the untreated animals (Fig. 2D). At 60 dpi, the group treated with
only DB289 still showed high rates of weight loss, even more than
the untreated mice group (Fig. 2D). Cure assessment evaluated by
both hemoculture and PCR did not reveal a parasitological cure in
any mice groups (Table 1).
Since our recent study demonstrated the high efficacy of DB766
upon T. cruzi infection in vivo and in vitro [27], its combination with
Bz was evaluated. Using the same therapy scheme as above, we
found that the treatment of infected mice with 50 mg/kg/day of
Bz or DB766 (ip.) or with DB766 (ip.) plus Bz (50 mg/kg/day
each) resulted in decreases in mice parasitemia by about 90%,
.96% and 100%, respectively, as compared to the untreated mice
group (Fig. 3A, Table 2). The analysis of cumulative mortality
revealed that while DB766 treated, Bz treated and untreated
groups resulted in 50, 12.5 and 100% of death, the combined
therapy of Bz plus DB766 resulted in 100% of protection, avoiding
animal death (Fig. 3B). We found at 20 dpi, that the Bz treated
and the combined therapy group showed partial restoration of the
mice body weight compared to uninfected mice, however, the
group treated with DB766 alone displayed even higher body
weight loss than that of the untreated mice group (Fig. 3C).
In these experimental groups, at the 14 dpi, we found that the
T. cruzi infection led to an increase in biochemical markers,
resulting in a rise of 2- and 29-fold for GPT and CK levels,
respectively (Fig. 3 D–E). Bz treatment alone did not reverse the
hepatic damage induced by parasite infection [35], however,
DB766 alone or in combination with Bz produced a decrease of
about 69% and 57% in GPT levels when compared to untreated
control (Fig. 3E). Muscle lesions, as evaluated by CK plasma levels
Table 1. Cure assessment of DB289 and DB766 combined or not with benznidazole (Bz) in murine model of acute T. cruzi-
infection.
1
Experimental groups Therapy route
(2,3)
Number of surviving/total




Number of negative blood
PCR samples/number of mice
Uninfected 13/13 - -
Untreated - 4/15 0/4 0/4
Bz 50 mg/kg/day p.o. 14/15 11/14 0/14
DB289 25 mg/kg p.o. 5/6 2/5 0/5
DB289 25 mg/kg+Bz 50 mg/kg p.o.+p.o. 6/6 1/6 0/6
DB766 50 mg/kg ip 6/15 0/6 0/6
DB766 50 mg/kg+Bz 50 mg/kg ip+p.o. 15/15 3/15 2/15
DB766 50 mg/kg p.o. 3/7 1/3 1/3
DB766 50 mg/kg+Bz 50 mg/kg p.o.+p.o. 8/8 0/8 0/8
1Swiss male mice weight 20 to 24 g inoculated with 10
4 blood trypomastigotes (Y strain).
Treatment was initiated at 5u dpi followed by 20 daily doses.
2Intraperitoneal – ip.
3per oral – p.o.
doi:10.1371/journal.pone.0022155.t001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22155Figure 2. Activity of DB289 alone or in combination with benznidazole (Bz) upon T. cruzi-infection in mice. (A): Parasitemia curve of
infected mice that were either not treated or treated at 5 and 8 dpi with 25 and 50 mg/kg/day DB289 and 100 mg/kg/day Bz. (B): Parasitemia curve,
(C) Cumulative Mortality and (D) Ponderal Curve of infected mice treated or not for twenty daily doses with 25 mg/kg/day DB289 combined or not
with 50 mg/kg/day.
doi:10.1371/journal.pone.0022155.g002
Table 2. Parasitemia peak of T. cruzi-infected mice treated or not with DB289 and DB766 associated or not with Benznidazole (Bz).
Experimental group Therapy route Parasitemia peak (610




1 p.o. 9.6610.2 (93%)*
DB766 50 mg/kg
1 ip 0.961.1 (99.4%)*
DB766 50 mg/kg+Bz 50 mg/kg
1 ip+p.o. 0.060.0 (100%)
* and **
Untreated
2 -9 5 612.8
Bz 50 mg/kg
2 p.o. 10.5614.4 (89%)*
DB766 50 mg/kg
2 p.o. 78688 (17%)
DB766 50 mg/kg+Bz 50 mg/kg
2 p.o.+p.o. 43.6631 (54%)*
DB766 50 mg/kg
2 ip 463 (96%)*
DB766 50 mg/kg+Bz 50 mg/kg
2 ip+p.o. 0.561 (99.5%)
* and **
DB289 25 mg/kg
2 p.o. 26.4614.4 (72%)*
DB289 25 mg/kg+Bz 50 mg/kg
2 p.o.+p.o. 1.261 (99%)
* and **
1 and 2=two independent representative studies.
*The single asterisk indicates statistically significant differences (p#0.05) between untreated and treated groups.
**The double asterisk indicates statistically significant differences (p#0.05) between the animal group that received the compound alone and in combination with Bz.
doi:10.1371/journal.pone.0022155.t002
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DB766 alone or combined with Bz resulted in reductions greater
than 91% when compared to untreated control (Fig. 3D).
Histopathological assays confirmed the high efficacy of DB766
combined with Bz which resulted in 100% reduction in cardiac
parasitism as compared to untreated animals (data not shown).
Cure assessment also revealed that the administration of 50 mg/
kg/day DB766 (ip.) plus 50 mg/kg/day Bz (p.o.) resulted in a 13%
parasitological cure, as evaluated by both hemocultive and PCR
analysis (Table 1).
Since DB766 shows high trypanocidal efficacy against T. cruzi in
vivo on oral administration at 100 mg/kg dose [27], we evaluated
another combination dosing regimen using sub-optimum oral
doses of both DB766 (50 mg/kg/day by p.o.) and Bz (50 mg/kg/
day by p.o.). DB766 (p.o.) alone reduced parasitemia by only
about 20% (Fig. 4A) and the mortality rates were reduced by
about 25% (data not shown). The administration of Bz plus
DB766 (both p.o) decreased the parasitemia by 54% (Fig. 4A,
Table 2), and gave a 100% mice survival rate similar to that of Bz
alone (data not shown). At 20 dpi, both Bz alone and the
Figure 3. Activity of DB766 (ip.) combined or not with benznidazole (Bz) upon T. cruzi-infection in mice. (A): Parasitemia curve, (B)
Cumulative Mortality and (D) Ponderal Curve of infected mice treated or not for twenty daily doses with 50 mg/kg/day DB766 combined or not with
50 mg/kg/day Bz. Plasma levels of (D) Glutamate pyruvate transaminase (GPT) and of (E) Creatinine kinase (CK) at 14 dpi from uninfected, untreated,
DB766, Bz and combined therapy treated mice.
doi:10.1371/journal.pone.0022155.g003
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however DB766 alone displayed similar body weight loss to that of
untreated animals (Fig. 4B). In the oral treatment studies, the only
parasitological cure noted by the hemoculture and PCR methods
was for the group treated with 50 mg/kg/day DB766 (p.o.)
(Table 1).
Discussion
Since the introduction of Nifurtimox and Bz (1960–1970),
despite the urgent need for new CD therapies, only allopurinol
and a few azoles have moved to clinical trials, possibly due to (i)
limited investment in this research field, (ii) an earlier mistaken
concept that during the later phase of CD parasitism was absent
and thus was not relevant to disease outcome and pathogenesis,
and (iii) the absence of universal standardized protocols for drug
screening [16]. The current profile for development of new drug
candidates for CD includes 1) efficacy against different stocks, 2)
efficacy against parasite forms relevant to the infection of
mammalian hosts for both the acute and chronic phases, 3) oral
administration in a minimum number of doses, 4) reduced toxicity,
5) yield high levels of tissue accumulation and long terminal half
lives and 6) low costs [16,39–40].
In this study using a murine model of T. cruzi acute infection,
the trypanocidal efficacy of pafuramidine (DB289) and the
arylimidamide DB766 either alone or in combination with
benznidazole was evaluated over a relatively short period of
treatment (20 days) employing both intraperitoneal and oral
administration.
Diamidine-containing compounds such as pentamidine and
furamidine are DNA minor groove binders with broad-spectrum
activity upon different species of human and veterinary pathogens
[20]. DB289 is the orally active prodrug of DB75 (furamidine) that
exerts microbicidal effects upon different pathogens including
Trypanosoma brucei, Pneumocystis jiroveci and Plasmodium falciparum,
[41–45]. Interestingly, DB289 showed good oral efficacy in
murine models of human African trypanosomes (HAT) suggesting
that sufficient quantities are absorbed from the mouse gastroin-
testinal tract, delivering this dicationic molecule across the gut
mucosa [43,46]. Similar to the therapy of HAT [43], oral efficacy
is a desirable feature for treatment of CD. However, in contrast to
the studies performed with T. brucei [43], DB289 alone was not
very effective against T. cruzi. This difference may be due to the
fact that in contrast to the African trypanosomes, T. cruzi has
intracellular stages living inside the cytoplasm of host cells, which
represents an additional obstacle for drug access and delivery. We
have found that the combination of Bz with DB289 improved the
efficacy of the diamidine by reducing parasitemia and resulted in
protection against mortality. In addition, this combined therapy
provided a 9-fold enhancement of activity compared to that of Bz
alone. Despite showing efficacy in Phase III clinical trials against
HAT and initial indications of low toxicity in African, Asian,
Caucasian and Hispanic populations, further studies with DB289
revealed considerable side effects leading to its withdrawal from
advanced human trials [16,43]. In fact, when higher doses of
DB289 ($100 mg/kg/day) were evaluated against T. cruzi
infection in vivo (unpublished data of DGJB), higher numbers of
circulating parasites and mortality rates were noticed as compared
to untreated mice, perhaps a consequence of compound toxicity.
A previous study by our group demonstrated the beneficial
effect of DB766 upon T.cruzi in vivo: a ten-day regimen of
treatment reduced both blood and cardiac tissue parasitism,
resulting in 90–100% protection against death even with an
infection with naturally resistant T. cruzi strain (Colombian) to
benznidazole [27]. Also, this AIA ameliorated electric heart
alterations and reduced hepatic and heart lesions induced by the
parasite infection [27]. Despite the promising trypanocidal effects
of this AIA via ip (up to 50 mg/kg/day) and by p.o (100 mg/kg/
day) routes which showed efficacy similar to Bz (100 mg/kg/day),
DB766 (as well as Bz) failed to provide a parasitological cure [27].
This result may be a consequence of the highly stringent protocol
employed (maximum of 10 days of drug administration). In fact,
previous studies performed in T. cruzi-infected murine models with
Bz and azoles reported high rates of parasitological cure only when
dosing was continued for longer periods ($40 days) [47–49],
which supports using longer periods of therapy for our
combination studies.
Our studies show that AIA are more active against T.cruzi than
diamidine compounds [26,50]. The greater activity may be related
to differences in their physical properties since AD are highly basic
molecules with pKa values near 11 while AIA pKa values are near
7. At physiological pH, AD are protonated and thus cationic
molecules while AIA are essentially neutral molecules enabling
their passive diffusion through the plasma membranes of both
parasites and host cells. This large difference in properties likely
affects absorption and distribution and may play an important role
in the different activity of these two classes of compounds.
Our data showed that while DB766 alone reduced parasitemia
giving a superior result to that of Bz, the combination of Bz and
DB766 leads to undetectable parasitism, thus improving the
efficacy of both compounds, especially Bz, whose potency was
Figure 4. Activity of DB766 (p.o.) combined or not with
benznidazole (Bz) upon T. cruzi-infection in mice. (A): Parasitemia
curve, and (B) Ponderal Curve of infected mice treated or not for twenty
daily doses with 50 mg/kg/day DB766 (per oral) combined or not with
50 mg/kg/day Bz.
doi:10.1371/journal.pone.0022155.g004
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therapy may reflect different targets (still incompletely understood
for both) and/or effects upon different parasite forms. As reported,
intracellular parasites must be considered the main parasite stage
for drug targeting in CD since T. cruzi is an obligatory intracellular
parasite [28].
As previously reported, DB766 displayed oral efficacy against an
experimental T. cruzi infection when high but non-toxic doses
(100 mg/kg/day) are employed [27]. However, when we evaluated
the p.o. treatment with Bz and DB766 using sub-effective doses of
both compounds (50 mg/kg/day each), the combined therapy only
enhanced the activity of the AIA by 1.8 fold. The combined therapy
showed a lower effect on parasitemia (but not on mortality rates) as
compared to Bz treatment alone, suggesting an antagonistic effect
that deservesto befurtherexplored.One out ofthreesurviving mice
treated with DB766 by p.o. was cured as assessed by both
hemocultive and PCR analysis. Although we did not find a
considerable reduction in the mean parasitemia in this mice group,
the cured animal was the one that displayed the lowest level of
circulating parasitism, reaching undetectable parasitism (by light
microscopy counting) after 23 dpi.
Although no visible adverse effects were noticed for DB289 and
DB766, when they were used alone, both increased the cachexia
induced by the parasite infection. This effect raises the possibility
of drug toxicity and/or up-regulation of inflammatory mediator
levels such as TNF-alpha that is implicated in loss of mice weight
during T. cruzi acute infection [51]. Although no detectable acute
toxicity was observed in mice treated up to a cumulative dose of
200 mg/kg/day of DB766 [27] and 100 mg/kg/day DB289 [43],
and our data showed reduced hepatic and muscle lesions during
the treatment of infected mice with DB766, a detailed biochemical
and histopathological analysis is needed to clarify this matter.
The measurement of pro and anti-inflammatory cytokines in the
plasma of infected and treated mice would contribute to the
understanding of the possible role of these mediators upon drug
toxicity and efficacy. Although no data is available for AIA, some
studies suggest a regulatory effect by pentamidine upon pro-
inflammatory cytokines [52–53]. Additionally, Bz down-regulates
the synthesis of TNF-alpha by murine stimulated macrophages
[54], ameliorates LPS-induced inflammatory response in mice by
decreasing peak levels of this serum cytokine [55] and markedly
reduces the production of pro-inflammatory cytokines and NO-
derived metabolites in experimentally T. cruzi-infected rats [56].
These data may explain the weight recovery found in Bz-infected
treated mice as compared to untreated mice since this pro-
inflammatory mediator is strongly expressed in T. cruzi-infected
mice [56–57], and is thought to be related to mice weight loss [51].
In our studies, we found a correlation between mice cachexia and
mortality rates, including in the DB766 groups (ip. and p.o.) that
may explain the lower protection against animal mortality in the
animal groups that only received the AIA.
In conclusion, this study has shown that DB766 is much more
potent in this mouse experimental model of T. cruzi infection than
DB289 and that the trypanocidal activity is improved by
combination therapy of both AD and AIA with Bz. Our data
support additional studies with other diamidines and AIAs alone
or in combination with other drugs with the goal of identification
of new candidate therapies for the treatment of Chagas disease.
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